0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Eli Lilly (LLY) Completes Acquisition of Verve Therapeutics | LL - GuruFocus
Is Verve Therapeutics Inc. a good long term investmentExplosive returns - Autocar Professional
Lilly completes acquisition of Verve Therapeutics to advance one - GuruFocus
Lilly Completes Acquisition Of Verve Therapeutics - Nasdaq
Eli Lilly completes acquisition of Verve Therapeutics - TipRanks
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company - Eli Lilly and Company
Lilly completes Verve Therapeutics acquisition for cardiovascular treatments - StreetInsider
Lilly Acquires Verve Therapeutics, Targets One-Time Cardiovascular Treatment | LLY Stock News - Stock Titan
Verve Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia
Lilly completes tender offer for Verve Therapeutics shares - Investing.com
Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly
Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - MSN
What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN
Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex
What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com
(VERV) Trading Advice - news.stocktradersdaily.com
3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru
Lilly’s $1 billion CRISPR bet: what Verve means for gene editing - The Pharma Letter
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa
Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks
Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN
Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):